Epstein-Barr virus (EBV) may be a cause of canine lymphoma
According to work published in the journal Virology by researchers at the University of Pennsylvania School of Veterinary Medicine and Penn's Perelman School of Medicine, the Epstein-Barr virus (EBV), which has been linked to a number of subtypes of lymphoma in humans, may also be responsible for causing some cases of canine lymphoma as well.
It should be noted that researchers are referring to it as an Epstein-Barr like virus, nor is there any evidence of the virus going from species to species. Rather, this study is highlighting the potential paradigm shift in understanding EBV and its association with lymphomas-- cancers that are not equivalent in dogs and humans but are the most frequently diagnosed canine cancers and which are especially prevalent in certain breeds, such as golden retrievers.
Read the full article online at Virology: Evidence of an oncogenic gammaherpesvirus in domestic dogs.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
